Oxurion NV
XBRU:OXUR

Watchlist Manager
Oxurion NV Logo
Oxurion NV
XBRU:OXUR
Watchlist
Price: 0.24 EUR -4% Market Closed
Market Cap: 616.8k EUR
Have any thoughts about
Oxurion NV?
Write Note

EV/EBITDA
Enterprise Value to EBITDA

-0.1
Current
-4.3
Median
4.2
Industry
Higher than median
Lower than industry value

Enterprise Value to EBITDA (EV/EBITDA) ratio is a valuation multiple that compares the value of a company, debt included, to the company’s cash earnings less non-cash expenses. EBITDA can be misleading at times, especially for companies that are highly capital intensive.

EV/EBITDA
-0.1
=
Enterprise Value
531.8k EUR
/
EBITDA
-7.2m EUR
All Countries
Close
Market Cap EV/EBITDA
BE
Oxurion NV
XBRU:OXUR
616.8k EUR -0.1
FR
Pharnext SCA
OTC:PNEXF
6T USD -222 155.3
US
Abbvie Inc
NYSE:ABBV
320.5B USD 15.6
US
Amgen Inc
NASDAQ:AMGN
140.8B USD 16
US
Gilead Sciences Inc
NASDAQ:GILD
114.4B USD 10.1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
105.4B USD 21.7
US
Epizyme Inc
F:EPE
94.1B EUR -508.6
AU
CSL Ltd
ASX:CSL
137B AUD 20
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
79.4B USD 15.5
US
Seagen Inc
F:SGT
39.3B EUR -58.1
NL
argenx SE
XBRU:ARGX
36.5B EUR -158
EBITDA Growth EV/EBITDA to Growth
BE
Oxurion NV
XBRU:OXUR
Average EV/EBITDA: 16.5
Negative Multiple: -0.1
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -222 155.3 N/A N/A
US
Abbvie Inc
NYSE:ABBV
15.6
9%
1.7
US
Amgen Inc
NASDAQ:AMGN
16
18%
0.9
US
Gilead Sciences Inc
NASDAQ:GILD
10.1
5%
2
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
21.7
13%
1.7
US
E
Epizyme Inc
F:EPE
Negative Multiple: -508.6 N/A N/A
AU
CSL Ltd
ASX:CSL
20
12%
1.7
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
15.5
11%
1.4
US
S
Seagen Inc
F:SGT
Negative Multiple: -58.1 N/A N/A
NL
argenx SE
XBRU:ARGX
Negative Multiple: -158 N/A N/A

EV/EBITDA Forward Multiples

Forward EV/EBITDA multiple is a version of the EV/EBITDA ratio that uses forecasted EBITDA for the EV/EBITDA calculation. 1-Year, 2-Years, and 3-Years forwards use EBITDA forecasts for 1, 2, and 3 years ahead, respectively.

1-Year Forward
EV/EBITDA
N/A
2-Years Forward
EV/EBITDA
N/A
3-Years Forward
EV/EBITDA
N/A